JP2017520573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520573A5 JP2017520573A5 JP2016575190A JP2016575190A JP2017520573A5 JP 2017520573 A5 JP2017520573 A5 JP 2017520573A5 JP 2016575190 A JP2016575190 A JP 2016575190A JP 2016575190 A JP2016575190 A JP 2016575190A JP 2017520573 A5 JP2017520573 A5 JP 2017520573A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- immunogenic composition
- cdtb
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 241000193163 Clostridioides difficile Species 0.000 claims description 24
- 108010010925 Clostridium actin-specific ADP-ribosyltransferase Proteins 0.000 claims description 21
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 13
- 229960005486 vaccine Drugs 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims description 6
- 101710182223 Toxin B Proteins 0.000 claims description 6
- 101710182532 Toxin a Proteins 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB1411306.2 | 2014-06-25 | ||
| GB1411371.6 | 2014-06-26 | ||
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005532A Division JP2020100625A (ja) | 2014-06-25 | 2020-01-17 | クロストリジウム・ディフィシル免疫原性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520573A JP2017520573A (ja) | 2017-07-27 |
| JP2017520573A5 true JP2017520573A5 (OSRAM) | 2018-07-12 |
| JP6688233B2 JP6688233B2 (ja) | 2020-04-28 |
Family
ID=53498986
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575190A Active JP6688233B2 (ja) | 2014-06-25 | 2015-06-25 | クロストリジウム・ディフィシル免疫原性組成物 |
| JP2020005532A Pending JP2020100625A (ja) | 2014-06-25 | 2020-01-17 | クロストリジウム・ディフィシル免疫原性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005532A Pending JP2020100625A (ja) | 2014-06-25 | 2020-01-17 | クロストリジウム・ディフィシル免疫原性組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (OSRAM) |
| EP (2) | EP3636278A3 (OSRAM) |
| JP (2) | JP6688233B2 (OSRAM) |
| CN (1) | CN106536544B (OSRAM) |
| BE (1) | BE1022949B1 (OSRAM) |
| BR (1) | BR112016030096B1 (OSRAM) |
| CY (1) | CY1122145T1 (OSRAM) |
| DK (1) | DK3160500T3 (OSRAM) |
| ES (1) | ES2749701T3 (OSRAM) |
| HR (1) | HRP20191864T1 (OSRAM) |
| HU (1) | HUE045936T2 (OSRAM) |
| LT (1) | LT3160500T (OSRAM) |
| MX (1) | MX374380B (OSRAM) |
| PL (1) | PL3160500T3 (OSRAM) |
| PT (1) | PT3160500T (OSRAM) |
| SI (1) | SI3160500T1 (OSRAM) |
| WO (1) | WO2015197737A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3056090A1 (en) * | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
| EP3810163A1 (en) | 2018-06-19 | 2021-04-28 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| WO1988009797A1 (en) | 1987-06-05 | 1988-12-15 | The United States Of America, As Represented By Th | Autocrine motility factors in cancer diagnosis and management |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ES2068989T3 (es) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoles como adyuvante en vacunas. |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| AU5972996A (en) | 1995-06-02 | 1996-12-18 | Incyte Pharmaceuticals, Inc. | Improved method for obtaining full-length cdna sequences |
| EP1169456B1 (en) | 1999-04-09 | 2012-07-11 | Intercell USA, Inc. | Recombinant production of Clostridium difficile Toxin A or Toxin B |
| WO2001073030A2 (en) | 2000-03-28 | 2001-10-04 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| AU2003304316A1 (en) * | 2002-11-08 | 2005-01-28 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| BR112014013876A2 (pt) * | 2011-12-08 | 2019-09-24 | Novartis Ag | vacina à base de toxina de clostridium difficile |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| CN112807422A (zh) * | 2012-12-05 | 2021-05-18 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 HR HRP20191864TT patent/HRP20191864T1/hr unknown
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en not_active Ceased
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
- 2015-06-25 MX MX2016017094A patent/MX374380B/es active IP Right Grant
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504993A5 (OSRAM) | ||
| JP6199036B2 (ja) | 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種 | |
| JP2008530245A5 (OSRAM) | ||
| CN115175696A (zh) | 包含白喉毒素交叉反应物质（crm）氨基酸序列的蛋白颗粒及其用途 | |
| RU2016111934A (ru) | Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы | |
| ES2633299T3 (es) | Polipéptidos inmunogénicos, los cuales comprenden un péptido matriz y un polipéptido L2, o un fragmento de éste | |
| US12053520B2 (en) | Glycan-masked engineered outer domains of HIV-1 gp120 and their use | |
| RU2008150400A (ru) | Новая детерминанта вирулентности в пределах структурного гликопротеина е2 вируса классической лихорадки свиней | |
| JP2013501007A5 (OSRAM) | ||
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| JP2009520758A5 (OSRAM) | ||
| Su et al. | RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses | |
| CA3211083A1 (en) | Compositions including sbi adjuvants and methods of use thereof | |
| TW201706296A (zh) | 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物 | |
| RU2016133598A (ru) | Композиция микобактериального антигена | |
| JP2017520573A5 (OSRAM) | ||
| JP2015529677A5 (OSRAM) | ||
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| Fernández et al. | Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine | |
| JP2009500037A (ja) | Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン | |
| Taherkhani et al. | Cloning of FliC gene from Salmonella typhimurium in the expression vector pVAX1 and evaluation of its expression in eukaryotic cells | |
| Zhang et al. | An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters | |
| RU2850338C2 (ru) | Композиции, содержащие адъюванты sbi, и способы их применения | |
| JP2025529904A (ja) | Ｓａｒｓ－ｃｏｖ－２免疫原性組成物および方法 | |
| HK40081102A (en) | Protein particles comprising a diphtheria toxin cross reacting material (crm) amino acid sequence and uses thereof |